期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

联合检测6种生化标志物对冠心病患者进行早期预后评价 被引量：5

下载PDF
导出
摘要 目的联合检测6种生化标志物,初步探讨其对冠心病患者早期诊断的价值。方法选择冠心病患者264例,记录患者住院期间发生的心脏事件,分为无心脏事件组、心脏事件组。联合检测肌钙蛋白I(cTnI)、氨基末端脑钠肽前体(NT-proBNP)、超敏C反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)。单核细胞趋化蛋白-1(MCP-1)和可溶性细胞间黏附分子(sICAM-1)浓度。结果心脏事件组6种生化标志物均高于非心脏事件组,差异有统计学意义(P<0.01);由cTnI、NT-proBNP、hs-CRP、MCP-1和sICAM-1组成的预测生化标志物组合,其预测住院期间心脏事件的敏感度为80.77%,特异度为76.32%。结论联合检测生化标志物对冠心病有较高的早期预测价值。
作者 赵一俏 刘北 付强 靳文 刘志樑
机构地区 广东省第二人民医院心内科 南方医科大学珠江医院心血管内科
出处 《广东医学》 CAS CSCD 北大核心 2011年第6期712-714,共3页 Guangdong Medical Journal
基金 广东省自然科学基金资助项目(编号:9151027501000063) 广东省自然科学基金立项项目(编号:5000168) 广东省自然科学基金资助项目(编号:915105150000056) 广州市科技计划项目(编号:2008Z1-E451)
关键词 冠心病 预后 生化标志物
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献10

  • 1VENGE P, LAGERQVIST B, DIDERHOLM E, et al. Clinicalperformance of three cardiac troponin assays in patientswith unsta- ble coronary artery disease ( a FRISC II substudy) [ J]. Am J Car-diol, 2002, 89(9) : 1035 - 1041.
  • 2MORROW D A, BRAUNWALD E. Future of biomarkers in acutecoronary syndromes: moving toward a muhimarker strategy [ J ]. Circulation, 2003, 108 (3) : 250 - 252.
  • 3VASAN R S. Biomarkers of cardiovascular disease : molecular ba-sis and practical considerations [ J]. Circulation, 2006, 113 (19) : 2335 - 2362.
  • 4JAMES S K, ARMSTRONG P, BARNATHAN E, et al. Troponinand C - reactive protein have different relations to subsequentmor- tality and myocardial infarction after acute coronary syndrome: aGUSTO -IV substudy[ J~. J Am Coil Cardiol, 2003, 41 (6) : 916 -924.
  • 5KOBUSIAK PROKOPOWICZ M, ORZESZKO J, MAZUR G, et al. Kinetics of chemokines in acute myocardial infarction [ J ]. Kardiol Pol, 2005, 62 (4) : 301 -314.
  • 6GURAY U, ERBAY A R, GURY Y, et al. Levels of souble adhe- sion molecular in various clinical p resentationation of coronaryatherosclerosis[J]. Int J Cardiol, 2004, 96 (2) : 235 - 240.
  • 7BLANKENBERG S, RUPPRECHT H J, POIRIER O, et al. Plas- ma concentrations and genetic variation of matrix metalloproteinase9 and prognosis of patients with cardiovascular disease [ J ]. Circu- lation, 2003, 107 (12): 1579-1585.
  • 8ANDERSON J L, ADAMS C D, ANTMAN E M, et al. ACC l AHA 2007 guidelines for the management of patients with unstableangina/non - ST - Elevation myocardial infarction : a report of the American College of Cardiology/American Heart Association TaskForce on Practice Guidelines ( Writing Committee to Revise the 2002 Guidelines for the Management of PatientsW ith UnstableAngina/Non - ST - ElevationMyocardial Infarction) developed in collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Asso-ciation of Cardiovascular and Pulmonary Rehabilitation and the So- ciety for Academic EmergencyMedicine [ J ]. J Am Coil Cardiol,2007, 50(7) : el -e157.
  • 9SABATINE M S, MORROW D A, DE LEMOS J A, et al. Multi- marker approach to risk stratification in non - ST elevation acutecoronary syndromes: simultaneous assessment of troponin I, C - reactive protein, and B - type natriuretic peptide [ J ]. Circula- tion, 2002, 105 ( 15 ) : 1760 - 1763.
  • 10高伟,王士雯.蛋白质组技术在心血管病研究中的应用现状[J].中华心血管病杂志,2004,32(11):1047-1049. 被引量：3

二级参考文献18

  • 1Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts and new words. Electrophoresis, 1998,19:1853-1861.
  • 2Unlu M, Morgan M, Minden J, et al. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis, 1997, 18:2071-2077.
  • 3Layh SG, Podtelejnikov A, Mann M, et al. Proteins complexed to the P1 adhesion of mycoplasma pneumoniae. Microbiology, 2000,146:741-747.
  • 4Dayal B, Ertel NH. ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res,
  • 5McDonough JL, Neverova I, Van-Eyk JE, et al. Proteomic analysis of human biopsy samples by single two-dimensional electrophoresis: Coomassie, silver, mass spectrometry, and Western blotting. Proteomics, 2002, 2: 978-987.
  • 6Neverova Irina; Van-Eyk JE. Application of reversed phase high performance liquid chromatography for subproteomic analysis of cardiac muscle. Proteomics, 2002, 2: 22-31.
  • 7Taylor SW, Fahy E, Zhang B, et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol, 2003, 21: 281-286.
  • 8Huber LA, Pfaller K, Vietor I, et al. Organelle proteomics: implications for subcellular fractionation in proteomics. Circ Res, 2003, 92: 962-968.
  • 9Brookes PS, Pinner A, Ramachandran A, et al. High throughput two-dimensional blue-native electrophoresis: a tool for functional proteomics of mitochondria and signaling complexes. Proteomics, 2002, 2: 969-977.
  • 10Taylor SW, Warnock DE, Glenn GM, et al. An alternative strategy to determine the mitochondrial proteome using sucrose gradient fractionation and 1D PAGE on highly purified human heart mitochondria. J Proteome Res, 2002, 1: 451-458.

共引文献2

同被引文献28

  • 1Heart Protection Study Collaborative Group,Jonathan Emberson,Derrick Bennett,et al.C-reactive protein concentration and the vas-cular benefits of statin therapy:an analysis of20,536patients in the Heart Protection Study[J].Lancet,2011,377(9764):469-476.
  • 2Rani Khatib,Alistair Hall.Adherence to secondary prevention medicines by coronary artery disease patients-exploring barriers to inform interventions[J].J Am Coll Cardiol,2012,59:1460.
  • 3Nordmeyer J, Lurz P, Khambadkone S, et al. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation:acute and 1-year outcomes. Heart,2011,97(2) :118-123.
  • 4Akhtar M,Waked A, Bhat H, et al. Drug-eluting stent thrombosis after 2029 days of placement : longest ever reported interval between drug-eluting stent placement and very late thrombosis. Future Cardiol,2011,7 (6) :745-748.
  • 5Dresslerova I,Vojacek J. Diabetes mellitus and ischemic heart disease. Vnitr Lek,2010,56(4) :301-306.
  • 6Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab, 2010,12 ( 3 ) : 210-218.
  • 7Nakajima T, Honda T, Domon H, et al. Periodontitis-associated up-regulation of systemic inflammatory mediator level may increase the risk of coronary heart disease. J Periodontal Res ,2010, 45( 1 ) : 116-122.
  • 8Konduracka E,Galicka-Latala D, Cieslik G,et al. Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension. Diabetes Obes Metab ,2008,10 ( 9 ) :719-725.
  • 9Crisby M, Kubliekiene K, Henareh L, et al. Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease. Heart Vessels ,2009,24 (2) :90-95.
  • 10Emberson J,Bennett D,Link E.C-reactive protein concentra-tion and the vascular benefits of statin therapy:an analysis of 20,536patients in the Heart Protection Study[J]. The Lancet, 2011,17(3):639.

引证文献5

二级引证文献23

广东医学
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部